Williams Timothy — SEC insider filings
SEC reporting owner CIK 1748392. 19 insider filings on record with FilingPulse; latest filed 2026-11-16.
Transaction summary — filings shown
Covers all 19 filings on record, filed 2020-08-17 to 2026-11-16. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 12,000 shares, $11,280 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 16 legs across 11 filings — 151,749 shares, $1,466,078 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 11.
- Largest priced transaction: sale of 42,434 shares @ $8.27 ($350,755) in Vanda Pharmaceuticals Inc., filed 2026-03-04.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. (VNDA) | SVP & General Counsel | 17 | — | 16 legs · 151,749 sh · $1,466,078 | 10 |
| GERON CORP (GERN) | EVP and Chief Legal Officer | 2 | 1 leg · 12,000 sh · $11,280 | — | 1 |
Insider filings — Williams Timothy
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-16 | 4 | GERON CORP (GERN) | Purchase (P): 12,000 @ $0.94 | EDGAR |
| 2026-04-14 | 4 | GERON CORP (GERN) | Grant/award (A): 2,500,000 (derivative) @ $0 | EDGAR |
| 2026-03-04 | 4 | Vanda Pharmaceuticals Inc. (VNDA) | Sale (S): 42,434 @ $8.27 | EDGAR |
| 2026-02-19 | 4 | Vanda Pharmaceuticals Inc. (VNDA) | Grant/award (A): 125,000 @ $0 | EDGAR |
| 2025-03-04 | 4 | Vanda Pharmaceuticals Inc. (VNDA) | Tax withholding (F): 26,941 @ $4.76 | EDGAR |
| 2025-02-20 | 4 | Vanda Pharmaceuticals Inc. (VNDA) | Grant/award (A): 125,000 @ $0 | EDGAR |
| 2024-03-06 | 4 | Vanda Pharmaceuticals Inc. (VNDA) | Sale (S): 8,147 @ $4.41 · Sale (S): 8,941 @ $4.18 | EDGAR |
| 2024-02-21 | 4 | Vanda Pharmaceuticals Inc. (VNDA) | Grant/award (A): 125,000 @ $0 | EDGAR |
| 2023-06-15 | 4 | Vanda Pharmaceuticals Inc. (VNDA) | Sale (S): 14,600 @ $6.56 | EDGAR |
| 2023-03-06 | 4 | Vanda Pharmaceuticals Inc. (VNDA) | Sale (S): 8,437 @ $6.24 · Sale (S): 8,301 @ $6.25 | EDGAR |
| 2023-02-21 | 4 | Vanda Pharmaceuticals Inc. (VNDA) | Grant/award (A): 32,700 @ $0 · Grant/award (A): 77,500 (derivative) @ $0 | EDGAR |
| 2022-12-16 | 4 | Vanda Pharmaceuticals Inc. (VNDA) | Sale (S): 8,000 @ $7.01 | EDGAR |
| 2022-08-17 | 4 | Vanda Pharmaceuticals Inc. (VNDA) | Sale (S): 3,689 @ $10.42 · Sale (S): 4,611 @ $10.21 | EDGAR |
| 2022-03-02 | 4 | Vanda Pharmaceuticals Inc. (VNDA) | Grant/award (A): 32,700 @ $0 · Sale (S): 12,060 @ $11.09 · Grant/award (A): 77,500 (derivative) @ $0 | EDGAR |
| 2021-08-17 | 4 | Vanda Pharmaceuticals Inc. (VNDA) | Sale (S): 3,715 @ $16.15 | EDGAR |
| 2021-03-08 | 4 | Vanda Pharmaceuticals Inc. (VNDA) | Sale (S): 200 @ $17.88 · Sale (S): 5,400 @ $17.85 | EDGAR |
| 2021-03-03 | 4 | Vanda Pharmaceuticals Inc. (VNDA) | Sale (S): 11,856 @ $18.60 · Sale (S): 7,674 @ $18.54 | EDGAR |
| 2021-02-26 | 4 | Vanda Pharmaceuticals Inc. (VNDA) | Grant/award (A): 32,700 · Grant/award (A): 77,500 (derivative) @ $0 | EDGAR |
| 2020-08-17 | 4 | Vanda Pharmaceuticals Inc. (VNDA) | Sale (S): 3,684 @ $11.81 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-08-10 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1748392 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs